Altimmune

Altimmune-logo.jpg

Altimmune is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. By leveraging specific attributes of its two independent and complementary platform technologies, Altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer.

Our Densigen™ T-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one.

Altimmune’s RespirVec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. Altimmune’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current products.